Steris stock analysis
Steris (0XI8) Share Price & Analysis
0XI8 Stock Chart & Stats
- Day’s Range
- EUR 125.06 - EUR 125.06
- 52-Week Range
- EUR 125.06 - EUR 125.06
- Previous Close
- EUR 125.06
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 23.29B
- Enterprise Value
- EUR 22.03B
- Total Cash (Recent Filing)
- EUR 531.10M
- Total Debt (Recent Filing)
- EUR 2.05B
- Price to Earnings (P/E)
- 31.3
- Beta
- N/A
- Next Earnings
- Feb 10, 2027 (Est.)
- EPS Estimate
- 2.53
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.15%
Bulls Say, Bears Say
Bulls Say
Recurring Installed-base Revenue
STERIS combines equipment sales with recurring consumables, maintenance, lifecycle support and outsourced sterilization services. This installed-base model can make customer relationships durable, support revenue visibility, and create follow-on demand after initial capital deployment.
Strong Profitability And Balance Sheet
Improved profitability, substantial free cash flow and sharply lower debt strengthen STERIS's financial flexibility. The healthier capital structure can support investment, acquisitions and shareholder returns while providing greater resilience through changes in hospital and manufacturing demand.
Life Sciences Growth And Margin Strength
Life Sciences is showing both strong demand and attractive economics, with growth led by equipment and supported by consumables and services. Reshoring and localization activity may extend this opportunity, while high margins can support durable earnings contribution.
Bears Say
Underlying Margin Pressure
Inflation, lower productivity and accelerated investment are pressuring underlying margins despite reported expansion. If these costs persist, pricing may not fully protect profitability, limiting operating leverage and reducing the durability of recent earnings improvement.
Lower Near-term Cash Generation
The cash-flow decline shows that earnings are not converting as strongly in the current period, with inventory investment absorbing operating cash. Although tied partly to planned shipments, sustained working-capital needs could constrain funding flexibility and capital allocation.
Debt-funded Xodus Acquisition
The planned Xodus transaction could broaden STERIS's surgical portfolio, but its large cash consideration and debt financing may increase leverage and interest obligations after closing. Integration and execution will be important for the expected revenue, margin and EPS benefits to materialize.
Steris News
0XI8 FAQ
What was Steris’s price range in the past 12 months?
What is Steris’s market cap?
When is Steris’s upcoming earnings report date?
How were Steris’s earnings last quarter?
Is Steris overvalued?
Does Steris pay dividends?
What is Steris’s EPS estimate?
How many shares outstanding does Steris have?
What happened to Steris’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Steris?
What is the TipRanks Smart Score and how is it calculated?
Steris Stock Smart Score
Company Description
Steris
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. It also provides services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers.
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Daniel A. Carestio
- Employees
- 17,937
- Website
- www.steris.com
- Address
- 5960 Heisley Road, Mentor, OH, 44060, US
Steris (0XI8) Earnings & Revenues
0XI8 Earnings Call
Earnings Call SentimentPositive
The call was broadly positive: revenue, earnings and Life Sciences performance were strong; Healthcare demand and backlog remained resilient; AST trends improved and destocking was described as ended; and full-year EPS and Life Sciences growth guidance were raised. Offsetting factors included lower underlying Healthcare and AST margins, reduced AST growth guidance, lower year-to-date cash flow, restructuring charges and the lack of expected additional tariff refunds. Overall, the positive operating performance and raised company outlook significantly outweighed the stated challenges.
View all GB:0XI8 earnings summaries0XI8 Net sales Breakdown
- 73.00% U.S.
- 25.39% Other locations
- 1.61% Ireland
0XI8 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 6 |
| Technical Analysis | 1 | 1 | 0 |
| Moving Averages | 2 | 4 | 6 |













